Dana-Farber Cancer Institute | Strategic Alliance Partners

December 16, 2021

A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.

December 13, 2021

Acalabrutinib, with or without obinutuzumab, induced a significant efficacy benefit for patients with treatment-naïve chronic lymphocytic leukemia compared with ibrutinib or venetoclax plus obinutuzumab, according to findings presented during the 63rd ASH Annual Meeting and Exposition.

December 08, 2021

Datopotamab deruxtecan showed highly encouraging and durable efficacy through overall response rates in patients with advanced or metastatic triple-negative breast cancer.

December 06, 2021

Dr. Choueiri discusses the significance of the FDA approval of pembrolizumab as adjuvant therapy in renal cell carcinoma and key data from the pivotal phase 3 KEYNOTE-564 trial.

December 01, 2021

Researchers from Rutgers Cancer Institute of New Jersey and Dana-Farber Cancer Institute developed and evaluated a computational pipeline that utilizes information commonly provided in tumor sequencing assays to predict the origin of detected DNA alterations.

November 22, 2021

Dana-Farber Cancer Institute is proud to announce that 35 of its researchers have been named to the Highly Cited Researchers list of 2021 released today by the Institute for Scientific Information at Clarivate.

November 21, 2021

Matthew L. Meyerson, MD, PhD, is constantly curious, both about the world and the people around him and as one of the top cancer researchers on the planet, he has a talent for elevating younger scientists, turning obstacles into discoveries, and sensing future research opportunities.

November 19, 2021

Toni K. Choueiri, MD, discusses the FDA approval of adjuvant pembrolizumab in renal cell carcinoma.

November 19, 2021

Patients with lymphoid malignancies, especially those who have received recent anti-CD20 antibody therapy, have reduced humoral responses to the mRNA COVID-19 vaccines, and as such, should continue to take precautionary measures against COVID-19 infection irrespective of vaccination status.

November 19, 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the diagnostic and treatment landscape of chronic graft-vs-host disease.

November 10, 2021

Glenn J. Hanna, MD, discusses promising data reported with tipifarnib in patients with HRAS-mutated head and neck cancer.

November 10, 2021

The 9th Annual Giants of Cancer Care® awards ceremony was a featured event at the 39th Annual CFS®: Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow®, hosted by Physicians’ Education Resource® LLC.

November 04, 2021

Glenn J. Hanna, MD, discusses the role of second-line cetuximab (Erbitux) in head and neck cancer.

October 27, 2021

Ziad Bakouny, MD, MSc, discusses recent ongoing research into the genomic drivers and biology of tRCC that could lead to improved outcomes for patients.

October 20, 2021

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma. 

October 14, 2021

Toni Choueiri, MD, discusses key highlights from the 2021 Kidney Cancer Research Summit and exciting research efforts underway in renal cell carcinoma.

October 11, 2021

Irene Ghobrial, MD, discusses the key objectives of the PROMISE study in multiple myeloma.

October 11, 2021

Bradley McGregor, MD, discusses ongoing trials in patients with non-clear cell renal cell carcinoma (RCC).

September 29, 2021

The frontline triplet combination comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be highly active and well tolerated when used in the treatment of patients with chronic lymphocytic leukemia.

September 14, 2021

Sara M. Tolaney, MD, MPH, discusses progress made with escalation and de-escalation strategies in HER2-positive breast cancer, ongoing research with immunotherapy, and efforts being made to further move the needle forward.